CCRA Clinical Trial Monitoring Techniques 2 — Questions and Answers
Question 1: Centralized monitoring differs from on-site monitoring in that it:
- Requires CRAs to be physically present at the site
- Involves remote review of accumulating data to identify trends and signals (Correct answer)
- Is performed only for Phase IV trials
- Replaces all on-site monitoring activities
Correct answer: Involves remote review of accumulating data to identify trends and signals
Centralized monitoring uses statistical analysis and remote data review to detect data anomalies, enrollment patterns, and compliance signals without requiring a site visit.
Question 2: Which of the following is an example of a critical process that should be prioritized during risk-based monitoring?
- Number of typos on non-critical CRF fields
- Informed consent process and documentation (Correct answer)
- Sponsor logo placement on patient materials
- Office hours of site administrative staff
Correct answer: Informed consent process and documentation
The informed consent process is a critical process because failures directly affect subject rights and can invalidate subject participation from a regulatory standpoint.
Question 3: A 'trigger' in risk-based monitoring refers to:
- The signal that prompts an unplanned site visit or escalated review based on predefined thresholds (Correct answer)
- The activation of the randomization system
- The date the site submits the first CRF page
- A sponsor instruction to increase enrollment pace
Correct answer: The signal that prompts an unplanned site visit or escalated review based on predefined thresholds
Triggers are predefined thresholds or signals (e.g., high query rate, low consent rate) that prompt escalated monitoring actions such as additional on-site or centralized review.
Question 4: At a Site Closeout Visit (COV), which activity is MOST critical for the CRA to confirm?
- Subject enrollment targets were met
- All trial materials are accounted for and essential documents are complete and archived (Correct answer)
- The site's financial invoices are paid
- Future trial opportunities are discussed with the investigator
Correct answer: All trial materials are accounted for and essential documents are complete and archived
During closeout, the CRA must ensure all investigational product is reconciled, essential documents are complete, and the site understands retention requirements for regulatory inspection readiness.
Question 5: When performing source document verification, the CRA confirms that source data is ALCOA+. What does 'ALCOA' stand for?
- Accurate, Legible, Contemporaneous, Original, Attributable
- Attributable, Legible, Contemporaneous, Original, Accurate (Correct answer)
- Accurate, Logged, Complete, Original, Attributed
- Attributed, Legal, Current, Official, Accurate
Correct answer: Attributable, Legible, Contemporaneous, Original, Accurate
ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate — the five core data quality attributes required for clinical trial data.
Question 6: A CRA identifies that a site coordinator has been backdating data entries in the EDC system. This should be classified as:
- A minor protocol deviation
- Data fraud requiring immediate escalation to the sponsor and possibly regulatory authorities (Correct answer)
- An administrative error requiring a simple correction
- A finding documented in the next routine monitoring report only
Correct answer: Data fraud requiring immediate escalation to the sponsor and possibly regulatory authorities
Backdating data is data fraud, which is a serious GCP violation requiring immediate escalation to the sponsor, and may necessitate reporting to regulatory authorities and potentially a for-cause audit.
CCRA Clinical Trial Monitoring Techniques 2
Centralized monitoring differs from on-site monitoring in that it: